Venus Medtech showcases its structural heart treatments at London Valves 2022 |

The company’s growing number of solutions for structural heart disease will be presented at several events during the conference between 27.-29. November

HANGZHOU, China, 25 November 2022 /PRNewswire/ — Venus Medtech is building an exciting pipeline of treatments for structural heart disease. The company will present its products at the conference taking place at ExCeL London 27.-29. November 2022 in his booth (#25), during a symposium and at the official launch of the TARGET multicenter clinical trial.

Structural heart symposium on 27 November

The company will also host a symposium on 27 November (Hall #4 at 17:30), where top researchers will discuss the latest findings and future plans for Venus Medtech tricuspid and pulmonary valve replacement systems. During this symposium, “The Right Valves for the Right Ventricle: Venus MedTech Tricuspid and Pulmonary Replacement Systems,” interventional cardiologists will have the opportunity to learn the latest in structural cardiac interventions.

Launch of TARGET CE trial for tricuspid valve replacement on November 28

In addition, Venus Medtech will officially launch the TARGET study at the conference. The TARGET study will evaluate the safety and performance of the Cardiovalve Tricuspid System – with its associated procedure – in reducing tricuspid regurgitation and its associated symptoms. The Cardiovalve System includes a valve and delivery system designed for tricuspid valve replacement through a transcatheter approach. The study will enroll one hundred patients in up to thirty medical centers. The patients will be followed for a period of up to five years.

The TARGET CE study will be officially launched at the Sunborn London Yacht Hotel on Monday, November 28 on 18:30.

Presentation of new data

The experiences with Cardiovalve and presentation of new data will be held in the following sessions:

  • Dr. Estevez-Loureiro, Eliminate tricuspid regurgitation: transfemoral CardioValve tricuspid replacement system (Tricuspid intervention session, 27 November13:30 – 15:00 at Interactive Case Corner 2).
  • Dr. Sheriff, Transcatheter transseptal mitral valve implantation: a new tool-in-the-box for patients with severe mitral regurgitation (TMVR Challenge Session, 27 November15:05 – 16:05, at Interactive Case Corner 2).
  • Dr. Schmidt, Transcatheter valve implantation in the mitral and tricuspid valve position(Rapid Fire Clinical Cases: Session 7, 29 November14:50 – 15:35 on the Stock Exchange).

About Venus Medtech: Increased global presence

Venus Medtech (stock code: 2500.HK) is committed to structural heart innovation. As the leading transcatheter defibrillator in medical devices China, Venus Medtech has established comprehensive solutions for structural heart disease. It now has a complete product pipeline covering all four heart valves, namely TAVR, TPVR, TMVR and TTVR, as well as hypertrophic cardiomyopathy, hypertensive renal denervation (RDN) therapy and relevant ancillary products.

Venus is now intensifying its presence in overseas markets and making important breakthroughs in registration and commercialization.

For more information

Visit our conference website:

See original content:

Venus Medtech showcases its structural heart treatments at London Valves 2022 |

Leave a Reply

Your email address will not be published.

Scroll to top